Commonwealth Coat of Arms of Australia

 

PB 98 of 2025

 

National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment (September Update) Instrument 2025

 

National Health Act 1953

 

I, REBECCA RICHARDSON, Assistant Secretary, PBS Listing, Pricing and Policy Branch, Technology Assessment and Access Division, Department of Health, Disability and Ageing, delegate of the Minister for Health and Ageing, make this Instrument under subsection 100(2) of the National Health Act 1953.

Dated 29 August 2025

REBECCA RICHARDSON

Assistant Secretary

PBS Listing, Pricing and Policy Branch

Technology Assessment and Access Division

 

 

1 Name

2 Commencement

3 Authority

4 Schedules

Schedule 1—Amendments

National Health (Efficient Funding of Chemotherapy) Special Arrangement 2024 (PB 31 of 2024)

 

  1.            This instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment (September Update) Instrument 2025.
  2.            This instrument may also be cited as PB 98 of 2025.
  1.            Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

 

Commencement information

Column 1

Column 2

Column 3

Provisions

Commencement

Date/Details

1. The whole of this instrument

1 September 2025

1 September 2025

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

  1.             Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

This instrument is made under subsection 100(2) of the National Health Act 1953.

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

 

 

 

 

  1.                      Schedule 1, Part 1, entry for Pemetrexed in the form Powder for I.V. infusion 500 mg (as disodium)

omit:

 

 

 

Pemetrexed APOTEX

 

  1.                      Schedule 1, Part 1, entry for Vinorelbine in the form Solution for I.V. infusion 50 mg (as tartrate) in 5 mL

omit:

 

 

 

Navelbine

 

  1.                      Schedule 2, entry for Ondansetron in the form Tablet 4 mg (as hydrochloride dihydrate)

omit:

 

 

 

APOOndansetron

C5778

 

4

0

V5778

  1.                      Schedule 2, entry for Ondansetron in the form Tablet 8 mg (as hydrochloride dihydrate)

omit:

 

 

 

APOOndansetron

C5778

 

4

0

V5778